Skip to main content

Table 2 Univariate analysis predicting necrosis at PC-RPLND

From: Predicting necrosis in residual mass analysis after retroperitoneal lymph node dissection: a retrospective study

  Necrosis Teratoma orviable GCT PValue
Components at orchiectomyhistology (%):    
Embryonal 22.7 ± 30.1 32.9 ± 29.7 0.370
Yolk sac 4.3 ± 11.5 4.1 ± 8.0 0.737
Teratoma 12.7 ± 23.7 13.8 ± 17.1 0.502
Endodermal sinus 1.7 ± 4.5 5.0 ± 11.7 0.628
Retroperitonial node size    
RP node cm before chemotherapy 6.5 ± 4.1 6.1 ± 5.5 0.849
RP node cm after chemotherapy 3.2 ± 1.8 5.3 ± 4.8 0.331
Relative change in RP node size 31.9 ± 48.3 9.4 ± 38.8 0.044
Absolute change in RP node size 3.2 ± 2.9 0.78 ± 2.9 0.053
Relative reduction in RP node 56.4 ± 14.0 26.2 ± 20.1 <0.001
Relative enlargement in RP node 35.6 ± 44.1 60.1 ± 22.5 0.425
Serum markers    
hCG after chemotherapy 0.0 0.0 **
AFP after chemotherapy 1.3 ± 0.4 22.1 ± 49.3 <0.001
Relative change in AFP afterchemotherapy 15.7 ± 46.7 −83.7 ± 5.13 0.075
LDH after chemotherapy 307.7 ± 60.7 324.0 ± 65.8 0.399
Relative change in LDH afterchemotherapy 1.5 ± 15.9 0.68 ± 27.4 0.915
  1. ** unable to calculate. Data expressed as mean ± standard deviation. AFP, alpha-fetoprotein; GCT, germ cell tumor; hCG, human chorionic gonadotropin; LDH, lactate dehydrogenase; PC-RPLND, post-chemotherapy retroperitoneal lymph node dissection; RP, retroperitoneal.